project id: TCGA-UCEC; case submitter id: TCGA-AX-A3FV; source center: 23; state: released; a260 a280 ratio: 1.86; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.7; rna integrity number: 8.7; age at index: 62; days to birth: -22752; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Alive; year of birth: 1947; age at diagnosis: 22752; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: -6.0; figo stage: Stage IIIA; icd 10 code: C54.1; last known disease status: not reported; morphology: 8380/3; primary diagnosis: Endometrioid adenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Endometrium; synchronous malignancy: No; tissue or organ of origin: Endometrium; tumor grade: Not Reported; year of diagnosis: 2009; treatment or therapy: not reported; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 799; initial weight: 100.0; oct embedded: false; preservation method: Unknown; sample id: 1661922c-cd0a-4b1e-a9bf-4aefe10654a6; sample submitter id: TCGA-AX-A3FV-01A; portion id: d5d650d9-74f9-409d-882d-3697b716be27; portion submitter id: TCGA-AX-A3FV-01A-11; slide id: ab1337a9-1fa9-433a-9b1a-73963cf61f32; slide submitter id: TCGA-AX-A3FV-01A-01-TS1; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 5.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 5.0; percent tumor cells: 90.0; percent tumor nuclei: 97.0; section location: TOP;